ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
FDA Approves Edwards’ Sapien 3 Ultra TAVR System
Friday, January 4, 2019
Submitted by
Source
Source Name: Edwards Lifesciences Corporation News Release
Edwards Lifesciences announced that the SAPIEN 3 Ultra system has received US Food and Drug Administration approval for transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients who are determined to be at intermediate or greater risk of open-heart surgery.
Printer-friendly
